Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Autor: Munseri PJ; Department of Internal Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania; Venhalsan, Karolinska Institutet, Sodersjukhuset, Stockholm, Sweden., Kroidl A; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany., Nilsson C; The Public Health Agency of Sweden, Solna, Sweden; Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden; Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden., Joachim A; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania., Geldmacher C; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany., Mann P; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany., Moshiro C; Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania., Aboud S; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania., Lyamuya E; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania., Maboko L; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania., Missanga M; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania., Kaluwa B; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania., Mfinanga S; National Institute for Medical Research-Muhimbili Medical Research Centre, Dar es Salaam, Tanzania., Podola L; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany., Bauer A; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany., Godoy-Ramirez K; The Public Health Agency of Sweden, Solna, Sweden., Marovich M; Walter Reed Army Institute of Research (WRAIR), Rockville, MD, United States of America and The Henry M. Jackson Foundation, Rockville, MD, United States of America., Moss B; Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, United States of America., Hoelscher M; National Institute for Medical Research-Mbeya Medical Research Center, Mbeya, Tanzania; Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany., Gotch F; Imperial College, London, United Kingdom., Stöhr W; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom., Stout R; Bioject Medical Technologies, 7180 SW Sandburg St, Tigard, Oregon, United States of America., McCormack S; Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom., Wahren B; Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden., Mhalu F; Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania., Robb ML; Walter Reed Army Institute of Research (WRAIR), Rockville, MD, United States of America and The Henry M. Jackson Foundation, Rockville, MD, United States of America., Biberfeld G; The Public Health Agency of Sweden, Solna, Sweden; Department of Microbiology, Tumor and Cell biology, Karolinska Institutet, Stockholm, Sweden., Sandström E; Venhalsan, Karolinska Institutet, Sodersjukhuset, Stockholm, Sweden., Bakari M; Department of Internal Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2015 Apr 15; Vol. 10 (4), pp. e0119629. Date of Electronic Publication: 2015 Apr 15 (Print Publication: 2015).
DOI: 10.1371/journal.pone.0119629
Abstrakt: Background: Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The present study explores whether HIV-DNA priming can be simplified by reducing the number of DNA injections and administration of combined versus separated plasmid pools.
Methods: In this phase IIa, randomized trial, priming was performed using 5 injections of HIV-DNA, 1000 μg total dose, (3 Env and 2 Gag encoding plasmids) compared to two "simplified" regimens of 2 injections of HIV-DNA, 600 μg total dose, of Env- and Gag-encoding plasmid pools with each pool either administered separately or combined. HIV-DNA immunizations were given intradermally at weeks 0, 4, and 12. Boosting was performed intramuscularly with 108 pfu HIV-MVA at weeks 30 and 46.
Results: 129 healthy Tanzanian participants were enrolled. There were no differences in adverse events between the groups. The proportion of IFN-γ ELISpot responders to Gag and/or Env peptides after the second HIV-MVA boost did not differ significantly between the groups primed with 2 injections of combined HIV-DNA pools, 2 injections with separated pools, and 5 injections with separated pools (90%, 97% and 97%). There were no significant differences in the magnitude of Gag and/or Env IFN-γ ELISpot responses, in CD4+ and CD8+ T cell responses measured as IFN-γ/IL-2 production by intracellular cytokine staining (ICS) or in response rates and median titers for binding antibodies to Env gp160 between study groups.
Conclusions: A simplified intradermal vaccination regimen with 2 injections of a total of 600 μg with combined HIV-DNA plasmids primed cellular responses as efficiently as the standard regimen of 5 injections of a total of 1000 μg with separated plasmid pools after boosting twice with HIV-MVA.
Trial Registration: World Health Organization International Clinical Trials Registry Platform PACTR2010050002122368.
Databáze: MEDLINE
Externí odkaz: